FT873 / Fate Therap - LARVOL DELTA

iPSC-derived NK cells exhibit potent in vitro and in vivo tumorcidal activity against patient-derived glioblastoma stem cells (GSCs) (SNO 2022) - " We performed pre-clinical studies to characterize the tumoricidal activity of FT573 against glioblastomas. Our results demonstrate great promise of FT538 as a glioblastoma therapy, with plans for translation into a first-in-human clinical trial."

Preclinical • Brain Cancer • Glioblastoma • Hematological Malignancies • Lymphoma • Oncology • Solid Tumor • CASP3 • CD276 • GZMB • IL15

FT573: Preclinical development of multiplexed-engineered iPSC-derived NK cells expressing a novel camelid nanobody chimeric antigen receptor (CAR) targeting pan-cancer antigen B7-H3 (AACR 2022) - "Further enhancement of anti-tumor efficacy was seen when combined with therapeutic antibodies, including trastuzumab and cetuximab. We have successfully produced and validated the specificity and function of an engineered camB7-H3 CAR-iNK cell exhibiting robust target killing and on-target specificity. We have successfully produced and validated the specificity and function of an engineered camB7-H3 CAR-iNK cell exhibiting robust target killing and on-target specificity. To our knowledge, this is the first camelid nanobody antigen recognition domain reported in a CAR-NK cell to be used as an off-the-shelf immunotherapy. The combining camB7-H3 CAR-NK with monoclonal antibodies targeting HER2 and EGFR as a dual targeting approach will add additional tumor specificity, further increase the efficacy of tumor cell elimination and prevent antigen escape."

IO biomarker • Pan tumor • Preclinical • Brain Cancer • Genito-urinary Cancer • Glioblastoma • Head and Neck Cancer • Oncology • Prostate Cancer • Sarcoma • Soft Tissue Sarcoma • Solid Tumor • CD276 • EGFR • HER-2 • IFNG • IL15 • LAMP1

Fate Therapeutics Announces Abstract Highlighting FT538 and FT573 Programs Selected for Presentation at SITC 2021 Annual Meeting Press Conference (GlobeNewswire) - "Dr. Miller’s presentation will describe the anti-tumor activity of the Company’s FT538 clinical product candidate as monotherapy and in combination with an NK cell engager targeting B7-H3....The presentation will also describe the integration of a novel chimeric antigen receptor (CAR) construct targeting B7-H3 into the master induced pluripotent stem cell (iPSC) line of FT538 to create the Company’s preclinical product candidate FT573, a B7-H3-targeted CAR NK cell incorporating multiple anti-tumor modalities."

Preclinical • Brain Cancer • CNS Tumor • Glioblastoma • Oncology